No effect of levothyroxine on hemoglobin in older adults with subclinical hypothyroidism: pooled results from two RCTs.

Du Puy, Robert S; Poortvliet, Rosalinde K E; Mooijaart, Simon P; Stott, David J; Quinn, Terry; Sattar, Naveed; Westendorp, Rudi G J; Kearney, Patricia M; McCarthy, Vera J C; Byrne, Stephen; Rodondi, Nicolas; Baretella, Oliver; Collet, Tinh-Hai; van Heemst, Diana; Dekkers, Olaf M; Jukema, J Wouter; Smit, Johannes W A; Gussekloo, Jacobijn; den Elzen, Wendy P J (2022). No effect of levothyroxine on hemoglobin in older adults with subclinical hypothyroidism: pooled results from two RCTs. Journal of clinical endocrinology and metabolism, 107(6), e2339-e2347. Endocrine Society 10.1210/clinem/dgac106

[img]
Preview
Text
DuPuy_JClinEndocrinolMetab_2022.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (247kB) | Preview

CONTEXT

Subclinical thyroid dysfunction and anemia are common disorders, and both have increasing prevalence numbers with advancing age.

OBJECTIVE

The aim of this study was to assess whether levothyroxine treatment leads to a rise in hemoglobin levels in older persons with subclinical hypothyroidism.

DESIGN

A pre-planned combined analysis of two randomized controlled trials.

PARTICIPANTS

Community-dwelling persons aged 65 years and older with subclinical hypothyroidism.

INTERVENTION

Participants were randomly assigned to levothyroxine or placebo treatment. The dose of levothyroxine was periodically titrated aiming at thyroid stimulating hormone (TSH) level within the reference range and mock titrations in the placebo group.

MAIN OUTCOME MEASURE

The main outcome measure was the change in hemoglobin level after 12 months.

RESULTS

Analyses included 669 participants (placebo n=337, levothyroxine n=332) with a median age of 75 years (range 65 to 97) and mean baseline hemoglobin of 13.8±1.3 g/dL. Although levothyroxine treatment resulted in a reduction in TSH from baseline after 12 months of follow-up compared to placebo, the change in hemoglobin level was not different between the levothyroxine and the placebo groups (-0.03 g/dL [95%CI -0.16 to 0.11]). Similar results were found in stratified analyses including sex, age or TSH levels. No difference in change of hemoglobin levels after 12 months was identified in 69 participants with anemia at baseline (-0.33 g/dL [95% CI -0.87 to 0.21]).

CONCLUSIONS

In persons aged 65 years and older with subclinical hypothyroidism, treatment with levothyroxine does not lead to a rise in hemoglobin levels, regardless of the presence of anemia.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Rodondi, Nicolas, Baretella, Oliver

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0021-972X

Publisher:

Endocrine Society

Funders:

[4] Swiss National Science Foundation ; [116] Swiss Heart Foundation = Schweizerische Herzstiftung

Language:

English

Submitter:

Pubmed Import

Date Deposited:

28 Feb 2022 07:07

Last Modified:

05 Dec 2022 16:11

Publisher DOI:

10.1210/clinem/dgac106

PubMed ID:

35218666

Uncontrolled Keywords:

Anemia RCT Thyroid older adults subclinical hypothyroidism

BORIS DOI:

10.48350/166117

URI:

https://boris.unibe.ch/id/eprint/166117

Actions (login required)

Edit item Edit item
Provide Feedback